Selecting and Utilizing Anti-BCMA Therapy in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, MD, and Parameswaran Hari, MD, MRCP, discuss considerations for selecting available B-cell maturation antigen (BCMA)–directed therapies for patients with myeloma and sequencing with these treatments through multiple lines of therapy.

For more resources and information regarding anticancer targeted therapies:

targeted oncology,oncology,cancer,